| | Treatment Found to Reduce Depression in Psoriasis
| | Treating psoriasis patients with adalimumab is associated with reduced depression and improved quality of life compared to placebo, according to research published in the May issue of the Journal of the American Academy of Dermatology. | |  |
|
|
| Biologic agents relieve chronic skin conditions where other treatments fail
| | | Biologic therapies can help patients with dermatologic conditions, providing anti-inflammatory benefits without significant effects on other organ systems, says Steven R. Feldman, M.D., Ph.D., professor of dermatology, pathology and public health sciences, Wake Forest Baptist Medical Center, Winston-Salem, N.C. |
| | Safety profile of biologics evolves, but long-term risk concerns remain
| | | New safety profile data continues to emerge on biologics used in psoriasis. Among the findings: Today's biologics do not appear to increase serious infection risk; the drugs' short-term cancer risk profile is promising; but concerns remain about long-term cancer risk with all biologics and cardiovascular risk with interleukin-12/23, ustekinumab (Stelara, Janssen Biotech). |
| | Clinicians concerned about safety, efficacy of biosimilar drugs
| |
| | Biosimilars are designed to mimic biologic agents, but they are not precise duplicates of these drugs. Biosimilars may prove useful for treating skin conditions such as psoriasis, but clinicians are waiting for guidance on the drugs from the Food and Drug Administration, which was still pending at press time. |
| | |
| 
Practice Tools
